

**Texas Prior Authorization Program
Clinical Criteria**

Drug/Drug Class

Enzymes

- [**Aldurazyme**](#)
- [**Ceprotin**](#)
- [**Elaprase**](#)
- [**Fabrazyme**](#)
- [**Galafold**](#)
- [**Naglazyme**](#)
- [**Nityr / Orfadin**](#)
- [**Revco**](#)
- [**Strensiq**](#)
- [**Vimizim**](#)

Note: Click the hyperlink to navigate directly to that section.

Clinical Criteria Information Included in this Document

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical criteria
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical criteria rules
- **Logic diagram:** a visual depiction of the clinical criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable
- **References:** clinical publications and sources relevant to this clinical criteria

Revision Notes

Annual review by staff

Removed criteria for Lumizyme – no longer on formulary

Updated references



Enzymes
Aldurazyme
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
ALDURAZYME 2.9MG/5ML VIAL	19585




Enzymes
Aldurazyme
Clinical Criteria Logic

1. Does the client have a **diagnosis of mucopolysaccharidosis I** (also called MPS I and/or Hurler-Scheie syndrome) in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Aldurazyme
Clinical Criteria Logic Diagram





Enzymes
Ceprotin
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
CEPROTIN 8002-1,200 UNITS VIAL	15483




Enzymes
Ceprotin
Clinical Criteria Logic

1. Does the client have a **diagnosis of severe congenital protein C deficiency** in the past 730 days?

Yes (Approve – 365 days)
 No (Deny)



Enzymes
Ceprotin
Clinical Criteria Logic Diagram





Enzymes
Elaprase
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
ELAPRASE 6MG/3ML VIAL	97047




Enzymes
Elaprase
Clinical Criteria Logic

1. Does the client have a **diagnosis of mucopolysaccharidosis II** (Hunter syndrome) in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Elaprase
Clinical Criteria Logic Diagram





Enzymes
Fabrazyme
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
FABRAZYME 5MG VIAL	22348
FABRAZYME 35MG VIAL	18997




Enzymes
Fabrazyme
Clinical Criteria Logic

1. Is the client less than (<) 2 years of age?
[] Yes (Deny)
[] No (Go to #2)
2. Does the client have a **diagnosis of Fabry disease** in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Fabrazyme
Clinical Criteria Logic Diagram





Enzymes
Galafold
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
GALAFOLD 123 MG CAPSULE	43641




Enzymes
Galafold
Clinical Criteria Logic

1. Is the client less than (<) 19 years of age?
[] Yes (Deny)
[] No (Go to #2)
2. Does the client have a **diagnosis of Fabry disease** in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Galafold
Clinical Criteria Logic Diagram





Enzymes
Naglazyme
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
NAGLAZYME 5MG/5ML VIAL	24744




Enzymes
Naglazyme
Clinical Criteria Logic

1. Is the client less than (<) 5 years of age?
 Yes (Deny)
 No (Go to #2)
2. Does the client have a **diagnosis of mucopolysaccharidosis VI** (MPS VI, Maroteaux-Lamy syndrome) in the past 730 days?
 Yes (Approve – 365 days)
 No (Deny)



Enzymes
Naglazyme
Clinical Criteria Logic Diagram





Enzymes
Nityr / Orfadin
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
NITYR 2 MG TABLET	43007
NITYR 5 MG TABLET	43006
NITYR 10 MG TABLET	43008
ORFADIN 2 MG CAPSULE	15662
ORFADIN 5 MG CAPSULE	15663
ORFADIN 10 MG CAPSULE	15664
ORFADIN 20 MG CAPSULE	39031
ORFADIN 4 MG/ML SUSPENSION	41268




Enzymes
Nityr / Orfadin
Clinical Criteria Logic

1. Does the client have a **diagnosis of hereditary tyrosinemia type 1** (HT-1) in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Nityr / Orfadin
Clinical Criteria Logic Diagram





Enzymes
Revcovi
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
REVCOVI 2.4 MG/1.5 ML VIAL	45525



Enzymes
Revco
Clinical Criteria Logic

1. Does the client have a **diagnosis of adenosine deaminase severe combined immunodeficiency disease (ADA-SCID)** in the last 730 days?


Yes (Go to #2)
 No (Deny)

2. Does the client have a diagnosis of **thrombocytopenia** in the last 365 days?

Yes (Deny)
 No (Approve – 365 days)



Enzymes
Revcovi
Clinical Criteria Logic Diagram





Enzymes
Strensiq
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
STRENSIQ 18 MG/0.45 ML VIAL	39938
STRENSIQ 28 MG/0.7 ML VIAL	39939
STRENSIQ 40 MG/ML VIAL	39857
STRENSIQ 80 MG/0.8 ML VIAL	39858




Enzymes
Strensiq
Clinical Criteria Logic

1. Does the client have a **diagnosis of perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)** in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Strensiq
Clinical Criteria Logic Diagram





Enzymes
Vimizim
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

Drugs Requiring Prior Authorization	
Label Name	GCN
VIMIZIM 5 MG/5 ML VIAL	36083




Enzymes
Vimizim
Clinical Criteria Logic

1. Is the client greater than or equal to (\geq) 5 years of age?
[] Yes (Go to #2)
[] No (Deny)
2. Does the client have a **diagnosis of mucopolysaccharidosis IVA** (also called Morquio A syndrome) in the past 730 days?
[] Yes (Approve – 365 days)
[] No (Deny)



Enzymes
Vimizim
Clinical Criteria Logic Diagram





Enzymes
Clinical Criteria Supporting Tables

Diagnosis of mucopolysaccharidosis I	
Required diagnosis: 1	
Look back timeframe: 730 days	
ICD-10 Code	Description
E7601	HURLER'S SYNDROME
E7602	HURLER-SCHEIE SYNDROME
E7603	SCHEIE'S SYNDROME

Diagnosis of adenosine deaminase severe combined immunodeficiency disease	
Required diagnosis: 1	
Look back timeframe: 730 days	
ICD-10 Code	Description
D8131	SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADENOSINE DEAMINASE

Diagnosis of severe congenital protein C deficiency	
Required diagnosis: 1	
Look back timeframe: 730 days	
ICD-10 Code	Description
D6859	OTHER PRIMARY THROMBOPHILIA

Diagnosis of mucopolysaccharidosis II (Hunter Syndrome)	
Required diagnosis: 1	
Look back timeframe: 730 days	
ICD-10 Code	Description
E761	MUCOPOLYSACCHARIDOSIS, TYPE II (HUNTER SYNDROME)

Diagnosis of Fabry disease
Required diagnosis: 1
Look back timeframe: 730 days

ICD-10 Code	Description
E7521	FABRY (-ANDERSON) DISEASE

Diagnosis of Pompe disease
Required diagnosis: 1
Look back timeframe: 730 days

ICD-10 Code	Description
E7402	POMPE DISEASE

Diagnosis of perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)
Required diagnosis: 1
Look back timeframe: 730 days

ICD-10 Code	Description
E8331	FAMILIAL HYPOPHOSPHATEMIA
E8339	OTHER DISORDERS OF PHOSPHOROUS METABOLISM

Diagnosis of Maroteaux-Lamy Syndrome
Required diagnosis: 1
Look back timeframe: 730 days

ICD-10 Code	Description
E7629	OTHER MUCOPOLYSACCHARIDOSES

Diagnosis of hereditary tyrosinemia type 1 (HT-1)
Required diagnosis: 1
Look back timeframe: 730 days

ICD-10 Code	Description
E7021	TYROSINEMIA

Diagnosis of thrombocytopenia
Required diagnosis: 1
Look back timeframe: 365 days

ICD-10 Code	Description
D693	IMMUNE THROMBOCYTOPENIC PURPURA

Diagnosis of thrombocytopenia**Required diagnosis: 1****Look back timeframe: 365 days**

ICD-10 Code	Description
D694	OTHER PRIMARY THROMBOCYTOPENIA
D6941	EVANS SYNDROME
D6942	CONGENITAL AND HEREDITARY THROMBOCYTOPENIA PURPURA
D6949	OTHER PRIMARY THROMBOCYTOPENIA
D695	SECONDARY THROMBOCYTOPENIA
D6951	POSTTRANSFUSION PURPURA
D6959	OTHER SECONDARY THROMBOCYTOPENIA
D696	THROMBOCYTOPENIA, UNSPECIFIED
D698	OTHER SPECIFIED HEMORRHAGIC CONDITIONS

Diagnosis of mucopolysaccharidosis IVA (Morquio A syndrome)**Required diagnosis: 1****Look back timeframe: 730 days**

ICD-10 Code	Description
E76210	MORQUIO A MUCOPOLYSACCHARIDOSES



Enzymes

Clinical Criteria References

1. Aldurazyme prescribing information. Cambridge, MA. Genzyme Corporation. December 2019.
2. Ceprotin Prescribing Information. Lexington, MA. Baxalta US Inc. August 2021.
3. Elaprase Prescribing Information. Lexington, MA. Takeda Pharmaceuticals USA, Inc. September 2021.
4. Fabrazyme prescribing information. Cambridge, MA. Genzyme Corporation. March 2021.
5. Lumizyme Prescribing Information. Cambridge, MA. Genzyme Corporation. March 2021.
6. Naglazyme prescribing information. Novato, CA. BioMarin Pharmaceutical Inc. December 2019.
7. Nityr prescribing information. Cambridge, United Kingdom. Cycle Pharmaceuticals Ltd. June 2021.
8. Orfadin prescribing information. Waltham, MA. Swedish Orphan Biovitrum. May 2019.
9. Vimizim prescribing information. Novato, CA. BioMarin Pharmaceutical Inc. December 2019.
10. 2014 ICD-10-CM Diagnosis Codes, Volume 1. 2014. Available at <http://icd10data.com>. Accessed on March 26, 2014.
11. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2022. Available at www.clinicalpharmacology.com. Accessed on July 13, 2022.
12. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on July 13, 2022.
13. Revcov Prescribing Information. Cary, NC. Chiesi USA, Inc. April 2021.
14. Galafold Prescribing Information. Philadelphia, PA. Amicus Therapeutics US, LLC. December 2021.

Publication History

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the **Revision Notes** on the first page of this document.

Publication Date	Notes
05/16/2014	Initial publication and posting to website
08/11/2017	<p>Annual review by staff</p> <p>Added criteria logic and diagram for Carbaglu, pages 10 and 11</p> <p>Added criteria logic and diagram for Ravicti, pages 28 and 29</p> <p>Added criteria logic and diagram for Vimizim, pages 31 and 32</p> <p>Added diagnoses codes for hyperammonemia due to NAGS deficiency, page 33</p> <p>Added diagnoses codes for urea cycle disorders and Morquio A syndrome, page 36</p> <p>Updated references, page 37</p>
11/22/2017	<p>Added criteria logic and diagram for Orfadin, pages 27-29</p> <p>Updated references, page 40</p>
12/06/2017	<p>Updated criteria logic and logic diagram for Fabrazyme, pages 19-20</p> <p>Added age check to criteria logic and logic diagram for Vimizim, pages 34-35</p>
12/27/2017	Updated criteria logic for Elaprase, page 16
03/30/2018	<p>Added GCNs for Nityr to 'Drugs Requiring PA', page 27</p> <p>Updated references, page 40</p>
03/28/2019	<p>Updated to include formulary statement (The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.) on each 'Drug Requiring PA' table</p> <p>Removed criteria for Carbaglu and Ravicti – these agents are now included in the Urea Cycle Disorder criteria</p>
09/11/2019	<p>Added GCN for Revcov to existing Adagen criteria</p> <p>Removed age requirement for Adagen criteria</p>
04/05/2021	Removed Adagen GCN (33971) – product has been discontinued

Publication Date	Notes
	Updated ICD-10 code for ADA-SCID for Revcovi Removed GCN for Ceprotin 400-600 units vial (15482) – not on formulary Updated age to \geq 2 years for Fabrazyme Updated references
04/15/2021	Annual review by staff Added criteria for Galafold (43641) Added criteria for Strensiq (39938, 39939, 39857, 39858) Updated references
07/13/2022	Annual review by staff Removed criteria for Lumizyme – no longer on formulary Updated references